Stock Price
104.50
Daily Change
-0.35%
Yearly
48.12%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,092.00 -44.00 -1.40% -17.15%
AbbVie 116.51 -2.15 -1.81% 11.08%
Adamas Pharmaceuticals 8.22 0.06 0.74% 91.16%
Aerie Pharmaceuticals 9.80 -0.35 -3.45% -24.62%
ALKERMES 22.47 -0.41 -1.79% 21.46%
Amgen 201.09 -2.88 -1.41% -10.55%
Antares Pharma 3.30 -0.12 -3.51% 5.77%
AstraZeneca 8,411.00 -97.00 -1.14% 8.25%
Bristol-Myers Squibb 56.53 -0.28 -0.49% -10.34%
Cara Therapeutics 12.80 -0.54 -4.05% -14.38%
Coherus Biosciences 18.37 -0.56 -2.96% -1.34%
Endo International Ordinary Shares 5.83 -0.22 -3.64% 8.16%
Flexion Therapeutics 9.12 -0.02 -0.22% -17.76%
Horizon Pharma 104.50 -0.37 -0.35% 48.12%
Jazz Pharmaceuticals 124.09 -5.22 -4.04% -13.39%
Eli Lilly 260.37 -1.63 -0.62% 76.59%
Merck & Co 79.16 -3.12 -3.79% -0.88%
Novartis 74.72 -1.85 -2.42% -7.82%
Prestige Brands 56.41 -3.00 -5.05% 53.83%
Pacira 51.63 -2.62 -4.83% -19.08%
Pfizer 54.00 3.11 6.11% 45.04%
Perrigo 37.78 -1.05 -2.70% -21.34%
Revance Therapeutics 12.83 -0.82 -6.01% -48.25%
Supernus Pharmaceuticals 30.61 -1.33 -4.16% 39.96%
Teva Pharmaceutical Industries 8.49 -0.19 -2.19% -13.54%
Bausch Health Companies Inc 31.80 -1.51 -4.53% 25.59%
Xeris Pharmaceuticals Inc 2.17 -0.02 -0.91% -52.10%
Zoetis 219.32 -3.85 -1.73% 35.83%

Indexes Price Day Year
NASDAQ 15492 -353.57 -2.23% 26.92%
US2000 2246 -85.52 -3.67% 21.06%

Horizon Pharma
Horizon Therapeutics plc is a biotechnology company that is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare, autoimmune and serious inflammatory diseases. The Company's portfolio is composed of approximately 12 medicines in the areas of rare diseases, gout, ophthalmology and inflammation. The Company has two reportable segments: the orphan and the inflammation segment. The orphan segment includes the medicines TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, UPLIZNA and also the Company’s research and development (R&D) programs. TEPEZZA is a monoclonal antibody and a targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R). KRYSTEXXA is an infused medicine for uncontrolled gout. The Company's other orphan segment medicines, RAVICTI, PROCYSBI and ACTIMMUNE, treats serious chronic diseases. The inflammation segment includes PENNSAID 2%, DUEXIS, RAYOS and VIMOVO medicines.